Compare MIRM & TGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | TGL |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 10.7M |
| IPO Year | 2019 | 2022 |
| Metric | MIRM | TGL |
|---|---|---|
| Price | $78.49 | $7.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $92.45 | N/A |
| AVG Volume (30 Days) | 790.7K | ★ 2.4M |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $471,794,000.00 | $2,305,713.00 |
| Revenue This Year | $53.78 | N/A |
| Revenue Next Year | $19.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.66 | N/A |
| 52 Week Low | $36.88 | $4.51 |
| 52 Week High | $79.95 | $780.00 |
| Indicator | MIRM | TGL |
|---|---|---|
| Relative Strength Index (RSI) | 69.86 | 52.91 |
| Support Level | $63.23 | $4.51 |
| Resistance Level | $66.77 | $8.78 |
| Average True Range (ATR) | 3.33 | 6.91 |
| MACD | 0.90 | -0.44 |
| Stochastic Oscillator | 98.15 | 11.99 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Treasure Global Inc. has created an online-to-offline e-commerce platform business model that offers consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retail or merchant settings. Its product is an internet application branded as the ZCITY app, which targets consumers by providing personalized deals based on their purchase history, location, and preferences. The Company has two reportable segments: (i) payment processing and e-commerce operation in its ZCITY platform, and (ii) customized software development service, and the majority of revenue comes from payment processing and e-commerce operation in its ZCITY platform.